Ajla Hrle
Chief Business Officer DISCO Pharmaceuticals
Seminars
Thursday 10th September 2026
From Platform Potential to Deal Reality: Aligning Modality, Targets & Evidence
12:00 pm
- Integrating pan-cancer or broadly applicable targets while maintaining specificity, and using this to evidence a scalable, differentiated discovery engine without compromising safety
- How do we determine which targets align with a given modality’s safety, selectivity and therapeutic potential?
- Sharing experience demonstrating the validation of a credible platform, including evolution from platform narrative to an asset-led story
- Discussing types of deals possible for platforms versus assets, and what is the minimum evidence needed for a deal?
